# Double Blind Trial in Children With Autism Spectrum Disorder

> **NCT06058962** · PHASE2 · COMPLETED · sponsor: **Paxmedica** · enrollment: 52 (actual)

## Conditions studied

- Autism Spectrum Disorder

## Interventions

- **DRUG:** Suramin Sodium

## Key facts

- **NCT ID:** NCT06058962
- **Lead sponsor:** Paxmedica
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-06-01
- **Primary completion:** 2021-01-15
- **Final completion:** 2021-03-15
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2023-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06058962

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06058962, "Double Blind Trial in Children With Autism Spectrum Disorder". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06058962. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*